Skip to main content

Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation

Buy Article:

$43.00 plus tax (Refund Policy)


There is increasing interest in tacrolimus‐minimization regimens. ASSET was an open‐label, randomized, 12‐month study of everolimus plus tacrolimus in de‐novo renal‐transplant recipients. Everolimus trough targets were 3–8 ng/ml throughout the study. Tacrolimus trough targets were 4–7 ng/ml during the first 3 months and 1.5–3 ng/ml (n = 107) or 4–7 ng/ml (n = 117) from Month 4. All patients received basiliximab induction and corticosteroids. The primary objective was to demonstrate superior estimated glomerular filtration rate (eGFR; MDRD‐4) at Month 12 in the tacrolimus 1.5–3 ng/ml versus the 4–7 ng/ml group. Secondary endpoints included incidence of biopsy‐proven acute rejection (BPAR; Months 4–12) and serious adverse events (SAEs; Months 0–12). Statistical significance was not achieved for the primary endpoint (mean eGFR: 57.1 vs. 51.7 ml/min/1.73 m2), potentially due to overlapping of achieved tacrolimus exposure levels (Month 12 mean ± SD, tacrolimus 1.5–3 ng/ml: 3.4 ± 1.4; tacrolimus 4–7 ng/ml: 5.5 ± 2.0 ng/ml). BPAR (months 4–12) and SAE rates were comparable between groups (2.7% vs. 1.1% and 58.7% vs. 51.3%; respectively). Everolimus‐facilitated tacrolimus minimization, to levels lower than previously investigated, achieved good renal function, low BPAR and graft‐loss rates, and an acceptable safety profile in renal transplantation over 12 months although statistically superior renal function of the 1.5–3 ng/ml tacrolimus group was not achieved. ( NCT00369161) is registered at .
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1:  Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary 2:  Department of Nephrology, University Medical Centre, Utrecht, The Netherlands 3:  Institute of Clinical and Experimental Medicine, Transplant Centre, Prague, Czech Republic 4: Division of Nephrology, Department of Internal Medicine, Academisch Ziekenhuis Maastricht, Maastricht, The Netherlands 5: Division of Nephrology, Hospital do Rim e Hipertensâo, São Paulo, Brazil 6: Department of Nephrology, Transplantology and Internal Medicine, Szczecin, Poland 7: Service de Néphrologie, Hôpital Pasteur, CHU Nice, France 8: Department of Nephrology-Dialysis-Organ Transplantation, Hôpital Rangueil, Toulouse, France 9: Departamento de Trasplantes, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 10: Novartis Pharma AG, Basel, Switzerland 11: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA 12: Servicio de Nefrología, Hospital del Mar, Barcelona, Spain

Publication date: 01 May 2012

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more